Program
ixekizumab
Also written as “Ixekizumab”, “LY2439821” and “80 mg ixekizumab”.
Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Spondylarthritis · Arthritis, Rheumatoid · Axial Spondyloarthritis, led by 3 companies.
Drug pageIxekizumab: every studyAll 56 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 361 open or running | phase 4since May 4, 2017 | Aug 25, 2009 | none ahead |
| Celltrion | 11 open or running | phase 1since Sep 23, 2025 | Sep 23, 2025 | none ahead |
| Samsung Bioepisits history only | 11 open or running | phase 1since Aug 20, 2026 | Aug 20, 2026 | Jun 9, 2027phase 1 · NCT07789964 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Celltrion only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 23, 2025First study: phase 1 study in Healthy ParticipantsFirst studyNCT07200986 · 218 enrolled · South Korea
TargetBeta
“Interleukin 17A inhibitor”ChEMBL 37, by rule
Other programs on IL17A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| secukinumabrule | Novartis | phase 4 | 128 |
| vunakizumabrule | Jiangsu HengRui Medicine | phase 4 | 17 |
| bimekizumabrule | UCB | phase 3 | 43 |
| sonelokimabrule | moonlake-immunotherapeutics-ag | phase 3 | 12 |
| simepdekinra | Eli Lilly | phase 2 | 7 |
| tibulizumabrule | Eli Lilly | phase 2 | 5 |
| SCT650Crule | Sinocelltech Group | phase 2 | 3 |
| UA026rule | usynova-pharmaceuticals-ltd | phase 1 | 1 |
Studies
The one study Celltrion leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07200986Healthy Participants · South Korea | 1 | Active, not recruiting | Mar 31, 2026 | 218 |
How it is read
Names in the registry
- “Ixekizumab”, 29 entries
- “LY2439821”, 3 entries
- “80 mg ixekizumab”, 2 entries
- “Ixekizumab 80 mg Q4W”, 1 entry
- “Ixekizumab 80 mg Q2W”, 1 entry
Conditions, from the studies’ own filings
- Psoriasis, 16 studies
- Arthritis, Psoriatic, 5 studies
- Spondylarthritis, 3 studies
- Arthritis, Rheumatoid, 3 studies
- Axial Spondyloarthritis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.